论文部分内容阅读
OBJECTIVE: To evaluate the effectiveness of the Traditional Chinese Medicine tonifying-kidney and regulating-liver therapy on diminished ovarian reserve (DOR).METHODS: The literature was comprehensively searched up to August 2019 using four Chinese and three English electronic databases to extract randomized clinical trials (RCTs) comparing Traditional Chinese Medicine tonifying-kidney and regulating-liver prescriptions (combined with hormone therapy or not) with Western Medicine.Data quality evaluation was conducted using the Cochrane risk of bias tool.Meta-analysis was conducted using Revman 5.3 software with effect estimates presented as mean difference (MD),risk ratio (RR),and 95％ confidence interval (CI).RESULTS: A total of nine RCTs with 512 participants were extracted and eligible for Meta-analysis.There were no significant differences between Chinese medicine and Western Medicine on basal serum follicle-stimulating hormone (FSH)level (MD 0.1 1,95％ C/-0.52 to 0.74,392 participants,seven trials),anti-Müllerian hormone level (MD 0.48,95％ C/-0.62 to 1.58,95 participants,two trials),and the FSH and luteinizing hormone ratio (MD 0.01,95％ C/-0.95 to 0.96,115 participants,two trials).Chinese medicine was more effective at improving Traditional Chinese Medicine symptom scores (TCMSS) (MD-2.39,95％ CI-3.83 to-0.94,160 participants,three trials),effective rate of TCMSS (RR 1.18,95％ C/1.02 to 1.36,160 participants,three trials),antral follicle count (AFC) (MD 0.55,95％ C/0.0.5to 1.04,155 participants,three trials),and FSH levels at 3 months post-treatment (MD-4.77,95％ CI -6.09 to-3.45,137 participants,two trials).CONCLUSION: Compared with Western Medicine,tonifying-kidney and regulating-liver therapy is more effective at relieving symptoms and improving AFC and FSH at 3 months post-treatment.